Table 1.
Clinical characteristics of 117 patients with AITL.
| Characteristic | Median | Rang | No. | % |
|---|---|---|---|---|
| Male sex | 76/117 | 65.0 | ||
| Age (year) | 62 | 19–84 | ||
| Age >60years | 67/117 | 57.3 | ||
| ECOG PS ≥2 | 19/117 | 16.2 | ||
| Stages III or IV | 110/113 | 97.3 | ||
| Stage IV | 65/113 | 57.5 | ||
| Extranodal involvement | 80/113 | 70.8 | ||
| Extranodal sites >1 | 52/113 | 46.0 | ||
| BM involvement | 16/100 | 16.0 | ||
| Liver involvement | 15/113 | 13.3 | ||
| Spleen involvement | 51/113 | 45.1 | ||
| B symptoms | 78/117 | 66.7 | ||
| Rash/Pruritus | 35/117 | 29.9 | ||
| Hemoglobin (g/L) | 109 | 39–160 | ||
| Anemia* | 86/117 | 73.5 | ||
| Platelet (x109/L) | 172 | 11–466 | ||
| <150 × 109/L | 43/117 | 36.8 | ||
| Lymphocyte (x109/L) | 1.0 | 0.2–6.9 | ||
| ≤1.1 × 109/L | 65/117 | 55.6 | ||
| Eosinophil (x109/L) | 0.16 | 0–2.34 | ||
| ≥0.5 × 109/L | 22/117 | 18.8 | ||
| Monocyte (x109/L) | 0.62 | 0.02–2.4 | ||
| ≥0.6 × 109/L | 59/117 | 50.4 | ||
| LDH (U/L) | 301 | 126–1020 | ||
| LDH level ≥245 U/L | 87/116 | 75.0 | ||
| β2 microglobulin (mg/L) | 4.38 | 1.22–14.87 | ||
| β2 microglobulin level ≥4.0 mg/L | 67/115 | 58.3 | ||
| Serum albumin (g/L) | 33.55 | 16.2–46.3 | ||
| Serum albumin level ≤35 g/L | 64/114 | 56.1 | ||
| Serum globulin (g/L) | 30.9 | 17.3–70 | ||
| Serum globulin level ≥35 g/L | 42/114 | 36.8 | ||
| IPI score | ||||
| Low risk | 7/113 | 6.2 | ||
| Low-intermediate risk | 26/113 | 23.0 | ||
| High-intermediate risk | 44/113 | 38.9 | ||
| High risk | 36/113 | 31.9 | ||
| PIT score | ||||
| Group 1 | 8/100 8.0 | |||
| Group 2 | 36/100 36.0 | |||
| Group 3 | 42/100 42.0 | |||
| Group 4 | 14/100 14.0 | |||
| Pathological finding | ||||
| EBER (+) | 49/69 | 71.0 | ||
| CXCL13 (+) | 57/77 | 74.0 | ||
| BCL-6 (+) | 66/78 | 84.6 | ||
| CD10 (+) | 61/92 | 66.3 | ||
| PD-1 (+) | 28/29 | 96.6 | ||
Abbreviations: BM, bone marrow; EBER, EBV-encoded early small RNA;ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; LDH, lactic dehydrogenase; PIT, Prognostic Index for Peripheral T-Cell Lymphoma, Unspecified.
*The presence of anemia was defined as the value of hemoglobin level <130 g/L for men and 115 g/L for women because the lower limit of normal was 130 g/L for men and 115 g/L for women based on our examination.